Prediction of Overall Survival and Progression-Free Survival by the ¹⁸F-FDG PET/CT Radiomic Features in Patients with Primary Gastric Diffuse Large B-Cell Lymphoma

Table 4

Univariate analysis (positron emission tomography).

	OS		PFS
	HR (95% CI)	value	HR (95% CI)	value
B Symptoms (yes vs. no)	0.257 (0.042–1.562)	0.140	0.213 (0.047–0.967)	0.045
SUVmax (≥3.7173 vs. <3.7173)	34.057 (0.009–127920.296)	0.401	33.806 (0.031–36395.638)	0.323
MTV (≥66.5 vs. <66.5)	12.972 (1.448–116.210)	0.022	8.049 (1.558–41.576)	0.013
Histogram based
Kurtosis (≥2.9179 vs. <2.9179)	13.090 (1.442–118.819)	0.022	4.293 (0.945–19.509)	0.059
Shape based
Volume (≥44.8928 vs. <44.8928)	10.139 (1.131–90.883)	0.038	6.426 (1.245–33.166)	0.026
Compacity (≥1.7565 vs. <1.7565)	116.242 (0.060–226261.65)	0.218	9.662 (1.161–80.383)	0.036
GLRLM
GLNU (≥178.7649 vs. <178.764)	10.968 (1.814–66.311)	0.009	14.642 (2.661–80.549)	0.002
RLNU (≥257.1264 vs. <257.126)	99.553 (0.060–164129.050)	0.224	8.487 (1.021–70.553)	0.048
NGLDM
Coarseness (≥0.0069 vs. <0.0069)	0.099 (0.011–0.884)	0.038	0.156 (0.030–0.804)	0.026

GLRLM, gray-level run length matrix; GLNU, gray-level nonuniformity; RLNU, run length nonuniformity; NGLDM, neighborhood gray-level difference matrix; SUV_max, maximum standardized uptake value; MTV, metabolic tumor volume; LDH, lactate dehydrogenase; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval. Asterisk () indicates significance with a value of <0.05 (shown in bold).